Physician profile
John W Lynch
NPI 1356364145
$5,314.65
in general payments reported to CMS, 2019-2025
34 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $1,022 · 2021: $811 · 2022: $781 · 2023: $749 · 2024: $483 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.73 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $877.35 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $845.05 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $763.55 | 2019-2025 | |
| Boston Scientific Corporation | $543.56 | 2019-2024 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Pfizer INC. | $295.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.71 | 2019-2024 | Brilinta, Andexxa, Lokelma |
| Amgen INC. | $239.81 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $196.06 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $156.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.47 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $94.93 | 2019 | |
| Impulse Dynamics (USA) INC. | $93.83 | 2022-2024 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $82.07 | 2020-2021 | |
| Abiomed | $75.79 | 2023-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $62.58 | 2019-2023 | Onpattro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $61.14 | 2019 | |
| Medtronic, INC. | $56.66 | 2022-2023 | Corevalve Evolut R |
| Amarin Pharma, INC. | $53.90 | 2019-2020 | |
| Lundbeck LLC | $49.61 | 2019-2021 | |
| Atricure, INC. | $48.61 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $46.81 | 2019-2025 | Camzyos |
| Novo Nordisk INC | $43.41 | 2019-2023 | Rybelsus, Ozempic |
| Cvrx, INC. | $26.82 | 2022-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $26.79 | 2019 | |
| Ge Healthcare | $26.11 | 2020 | |
| Merck Sharp & Dohme LLC | $25.71 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2025 | |
| Akcea Therapeutics, INC. | $15.32 | 2021 | |
| Cardiva Medical, INC. | $13.93 | 2023 | Cardiva Vascade 6/7f Vcs |
| Lexicon Pharmaceuticals, INC. | $13.91 | 2023 | Inpefa |
| Chiesi USA, INC. | $13.22 | 2019 | |
| Abbott Laboratories | $12.90 | 2022 | |
| Astellas Pharma US INC | $12.64 | 2022 | |
| Esperion Therapeutics, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.